Avalo Therapeutics (NASDAQ:AVTX) Earns Outperform Rating from Analysts at Wolfe Research

Stock analysts at Wolfe Research started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report issued on Thursday. The brokerage set an “outperform” rating and a $48.00 price target on the stock. Wolfe Research’s target price suggests a potential upside of 233.10% from the stock’s current price.

Several other equities research analysts also recently commented on AVTX. Citizens Jmp assumed coverage on shares of Avalo Therapeutics in a research report on Monday. They set an “outperform” rating and a $52.00 target price on the stock. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. HC Wainwright boosted their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Guggenheim assumed coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Avalo Therapeutics Stock Down 9.5%

Shares of AVTX opened at $14.41 on Thursday. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72. The business has a 50-day simple moving average of $15.54 and a two-hundred day simple moving average of $16.09. The stock has a market cap of $328.40 million, a PE ratio of -2.51 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. On average, equities research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Insiders Place Their Bets

In related news, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at $65,232.22. This represents a 52.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total value of $136,857.00. Following the sale, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at $297,346.70. This represents a 31.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,100 shares of company stock worth $764,724 in the last ninety days. Insiders own 3.03% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AVTX. BIT Capital GmbH acquired a new stake in shares of Avalo Therapeutics during the 3rd quarter worth approximately $25,000. PFS Partners LLC lifted its position in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the period. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the second quarter worth $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the third quarter worth $143,000. Finally, Jump Financial LLC bought a new stake in Avalo Therapeutics in the fourth quarter valued at $238,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.